Fiserv, Inc. FI

Key data

The business

Fiserv runs two engines off one meter. Merchant Solutions processes card payments for merchants and sells Clover, the cloud point-of-sale system, the small tablet and terminal on a coffee-shop counter that rings up the sale, tracks the inventory, and quietly lends the owner working capital. Financial Solutions is the back-office plumbing banks rent: the core account processing that thousands of US banks and credit unions run their deposits on, plus card issuing and digital banking. Fiserv takes a thin slice of every transaction, so payment volume is the master variable, and Clover's gross payment volume was the growth story the market underwrote all the way to a $238 stock and a 25-to-40-times multiple.

The moat is switching costs. A bank does not rip out the core it settles accounts on because a salesman called, and a merchant wired into Clover for payments, payroll, and lending does not casually unplug the register. That stickiness is real and still there. What left is the belief that the meter spins faster every year.

The numbers

Trailing twelve months: net revenue about $18.6B, GAAP earnings near $2.8B, and free cash flow of roughly $7.1B, a 21% free-cash yield on today's price. The break is not in the level, it is in the cadence.

Adjusted EPS, the two misses that broke it

Two quarters in line to beating, then two misses of 23% and 25%. A company that had trained the Street to expect metronomic beats missed twice in a row and cut the Clover growth it had guided, and a business valued on the reliability of its second derivative does not get to have an unreliable second derivative. The multiple did the rest.

What the Street now underwrites

The Street still pencils double-digit EPS growth, but consensus revenue barely moves, about $21.1B in 2027 rising 2.3% to $21.6B in 2028. That near-flat top line is the tell: analysts have re-cast a compounder as a cash cow that grows earnings through buybacks and margin, not volume. The variant this memo holds is narrower and duller than the bulls': $7.1B of present-tense free cash on a $34B company is being priced as if the cash itself is suspect or about to evaporate, and the single print that settles it is whether Clover's organic growth stabilizes in the high single digits or keeps sliding. FY2026's own full-year guidance is still not restated in this pull, the estimates jump straight to 2027, and that visibility vacuum is exactly what lets a cash machine sit at 8 times earnings.

Management

New chief executive Michael Lyons inherits the credibility problem, not the one who made it. Insiders bought nothing and sold nothing in the trailing twelve months, so no officer is stepping into the low with his own money, and none is fleeing either; plan status not disclosed. The uncomfortable arithmetic is the buyback: $7.1B of annual free cash funds heavy repurchases, but a chunk of the prior team's buying happened at $150 to $238, stock that is now $64, which turns "returning capital" into value destroyed and dressed as a dividend substitute. Whether the new team keeps buying here, at 8x, is the first real test of judgment. Compensation detail was not pulled this run.

How it fails or surprises you

Clover stalls (the fact my read explains least). If Clover's payment-volume growth keeps decelerating toward the low single digits over the next two quarters, "cash cow" curdles into "melting ice cube" and 8x is fair, not cheap. The number that would prove this memo wrong is Clover organic revenue growth printing below about 8%; that makes the slowdown structural, not cyclical.

Trust and the adjustments. The misses plus lingering scrutiny over revenue quality mean the live danger is a restatement or another guide-down revealing that the adjusted numbers flattered the real ones. The print that reveals it first: any 8-K revising prior segment figures. This is the one that would be permanent.

The re-rate (right tail). If Lyons delivers even two clean quarters that merely clear a reset bar, a business throwing off $7.1B of cash does not stay at 8x. A move to 12x forward earnings, still a discount to the 20.8x peer and far below its own 24-to-41x history, is 73% upside and requires no growth reacceleration at all, only restored trust.

Closing thoughts

A specific print settles this one, so name it: Clover's organic growth rate and whether the new CEO's first full-year guide holds. It is not a survival story, net debt of about $27B is roughly 4x EBITDA, real but serviceable against $7.1B of free cash. And it is not efficiently priced, because the gap between 8x and any credible normal multiple is too wide to be a fair fight. I judge the right tail the fatter one, because the cash flow is enormous and present-tense while the fears are about the slope of future growth, not solvency. But the left tail, a restatement, is the one that would be permanent, so it should dominate how large anyone lets this position get.

The bet is still that shopkeepers keep swiping through Fiserv's machines and Clover keeps winning counters. What breaks it is Clover's growth rate sliding below high single digits while trust stays broken. The pair to watch is Clover organic revenue growth against the new chief executive's first full-year guide: if both firm up, 8 times earnings on $7.1B of cash was a gift, and if Clover keeps sliding, it was a warning the price was telling the truth.